Humana Divests Gentiva Stake for $900M to Boost Liquidity

Key Facts

In a move aimed at refocusing its operational priorities, Humana has agreed to sell its interest in care provider Gentiva to an investor group for approximately $900 million. According to reports, this divestiture involves exiting its remaining stake in the home health and hospice care provider, as Humana seeks to utilize the cash proceeds for general corporate purposes and to bolster overall profitability.

This strategic shift occurs as the healthcare sector undergoes significant restructuring to strengthen balance sheets; for instance, major peer UnitedHealth Group reported a robust 8.6% revenue growth in its Q1 2024 earnings per search data. By securing this liquidity, Humana aims to optimize its financial positioning relative to industry peers, especially as inflationary pressures continue to impact healthcare service costs.

Regarding market performance, HUM shares stood at $364.46 (at close June 10, 2026), having traded between a low of $359.58 and a high of $369.34 according to market data. Investors are now looking toward upcoming catalysts, including U.S. employment data and future fiscal reports, to gauge how this divestiture will impact the company's long-term margin expansion.

Version History